Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CRAIG FORREST TELLER

Allopathic & Osteopathic Physicians Dermatology

NPI
1851351357
CMS profile
219600
Location
BELLAIRE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$243,515.15

330 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 6 of 7; records 251–300 of 330 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CRAIG FORREST TELLER

NPI 1851351357 · CMS profile ID 219600

Allopathic & Osteopathic Physicians / Dermatology

BELLAIRE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 7; records 251–300 of 330 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851351357?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CRAIG FORREST TELLER, NPI 1851351357, CMS profile ID 219600. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 330 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851351357?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CRAIG FORREST TELLER, NPI 1851351357, CMS profile ID 219600. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 330 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851351357?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CRAIG FORREST TELLER, NPI 1851351357, CMS profile ID 219600, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 7; records 251–300 of 330 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1851351357?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

330 matching records · $243,515.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 330 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 330.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $71.8002/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812201 CMS
Biofrontera Inc. $15.9202/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688571727 CMS
Novartis Pharmaceuticals Corporation $1,500.0002/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660008161 CMS
Regeneron Healthcare Solutions, Inc. $1,006.5002/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673488179 CMS
Galderma Laboratories, L.P. $15.2702/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687722673 CMS
AbbVie, Inc. $4,375.0002/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812195 CMS
Janssen Scientific Affairs, LLC $68.3302/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657609585 CMS
Regeneron Healthcare Solutions, Inc. $47.8802/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673488175 CMS
Regeneron Healthcare Solutions, Inc. $3,522.7502/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673488177 CMS
Regeneron Pharmaceuticals, Inc. $86.5802/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673510213 CMS
Galderma Laboratories, L.P. $8.6502/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687722671 CMS
Janssen Biotech, Inc. $0.4902/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658749137 CMS
Lilly USA, LLC $16.8802/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657735039 CMS
Regeneron Healthcare Solutions, Inc. $17.9302/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673488173 CMS
Novartis Pharmaceuticals Corporation $11.0802/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660008181 CMS
AbbVie, Inc. $4,375.0002/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812191 CMS
Allergan Inc. $2,000.0002/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671220583 CMS
Helsinn Therapeutics (U.S.), Inc. $17.2002/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655948187 CMS
Lilly USA, LLC $40.2502/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657731565 CMS
Lilly USA, LLC $78.0002/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657731567 CMS
Lilly USA, LLC $35.9602/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657748949 CMS
Lilly USA, LLC $26.0002/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657748951 CMS
AbbVie, Inc. $114.6002/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812205 CMS
Novartis Pharmaceuticals Corporation $12.9802/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660008179 CMS
AbbVie, Inc. $389.8001/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812183 CMS
AbbVie, Inc. $19.6901/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812193 CMS
AbbVie, Inc. $565.0001/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812203 CMS
AbbVie, Inc. $645.0001/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812207 CMS
AbbVie, Inc. $106.9101/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812209 CMS
Janssen Biotech, Inc. $0.4401/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658749129 CMS
Janssen Biotech, Inc. $12.9901/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658749133 CMS
Allergan Inc. $3.0601/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671220581 CMS
Allergan Inc. $5.9601/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671220575 CMS
Allergan Inc. $11.3901/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671220577 CMS
Regeneron Healthcare Solutions, Inc. $3,522.7501/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673488169 CMS
Regeneron Healthcare Solutions, Inc. $23.8201/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673488171 CMS
Janssen Scientific Affairs, LLC $975.0001/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657609583 CMS
LEO Pharma Inc. $1,050.0001/22/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687273961 CMS
TARO PHARMACEUTICALS USA, INC. $2,300.0001/22/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704148097 CMS
TARO PHARMACEUTICALS USA, INC. $315.6301/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704148099 CMS
Almirall LLC $1,500.0001/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676672415 CMS
Janssen Biotech, Inc. $0.8201/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658749123 CMS
AbbVie, Inc. $2.8301/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812313 CMS
AbbVie, Inc. $8.1801/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647812315 CMS
Lilly USA, LLC $2,800.0001/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657745607 CMS
Lilly USA, LLC $2,800.0001/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657748947 CMS
Lilly USA, LLC $2,800.0001/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657752333 CMS
Novartis Pharmaceuticals Corporation $16.4501/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660008177 CMS
Celgene Corporation $12.5901/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672723743 CMS
Lilly USA, LLC $2,800.0001/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657748945 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $243,515.15 330
PY2020 $96,998.13 163
PY2021 $95,015.98 203
PY2022 $175,919.03 316
PY2023 $265,037.01 355
PY2024 $210,278.28 354
PY2025 $219,985.05 309

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,097,707.89 543
PY2024 Recipient $507.43 3
PY2024 Principal investigator $1,401,159.23 581
PY2023 Principal investigator $619,404.95 202
PY2022 Principal investigator $922,540.73 143
PY2021 Recipient $11,400.00 1
PY2021 Principal investigator $752,004.96 125
PY2020 Recipient $6,722.74 3
PY2020 Principal investigator $753,353.67 159
PY2019 Recipient $5,372.41 6
PY2019 Principal investigator $821,486.03 104

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

543 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $8,420.82 12/31/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
A Prospective, Open-Label Study to Evaluate Subject Satisfaction with Overall Facial Appearance After Treatment with JUVeDERM Products in Medical Weight Loss (MWL) Subjects No dispute reported 06/30/2026 1202534109
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202534131
Principal investigator 1 ABBVIE INC. $10,083.36 12/31/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study No dispute reported 06/30/2026 1202534133
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202534135
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $500.00 12/24/2025 Non-covered Recipient Entity
Bellaire Dermatology Associates
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430908
Principal investigator 1 ABBVIE INC. $1,076.00 12/22/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202531638
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,837.83 12/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190302251
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,487.50 12/12/2025 Non-covered Recipient Entity
Bellaire Dermatology Associates
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430906
Principal investigator 1 Incyte Corporation $531.50 12/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240507247
Principal investigator 1 Incyte Corporation $750.00 12/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507273
Principal investigator 1 Incyte Corporation $1,139.40 12/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507307
Principal investigator 1 Incyte Corporation $1,899.00 12/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507312
Principal investigator 1 Incyte Corporation $1,899.00 12/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507316
Principal investigator 1 Incyte Corporation $1,899.00 12/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507320
Principal investigator 1 Incyte Corporation $11,810.30 12/08/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507299
Principal investigator 1 ABBVIE INC. $2,688.40 12/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202526580
Principal investigator 1 ABBVIE INC. $15,729.70 12/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202526808
Principal investigator 1 ABBVIE INC. $4,227.50 12/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202526810
Principal investigator 1 ABBVIE INC. $1,568.10 12/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202527464
Principal investigator 1 ABBVIE INC. $3,270.20 12/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202527470
Principal investigator 1 ABBVIE INC. $2,608.60 12/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527482
Principal investigator 1 Incyte Corporation $1,169.30 12/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240507243
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507337
Principal investigator 1 Incyte Corporation $20.40 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507342
Principal investigator 1 Incyte Corporation $30.81 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507346
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507351
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507356
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507361
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507364
Principal investigator 1 Incyte Corporation $33.18 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507368
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507388
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507393
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507398
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507415
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507419
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507452
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507456
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507461
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507483
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507487
Principal investigator 1 ABBVIE INC. $2,683.20 11/26/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202525534
Principal investigator 1 ABBVIE INC. $708.50 11/26/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202525536
Principal investigator 1 ABBVIE INC. $1,508.00 11/26/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202525562
Principal investigator 1 Incyte Corporation $956.70 11/25/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240507235
Principal investigator 1 Incyte Corporation $825.00 11/24/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507295
Principal investigator 1 Incyte Corporation $1,244.00 11/24/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507325
Principal investigator 1 Incyte Corporation $1,244.00 11/24/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507328
Principal investigator 1 Incyte Corporation $356.00 11/24/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507444
Principal investigator 1 Incyte Corporation $395.40 11/24/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507472
Principal investigator 1 Incyte Corporation $1,348.00 11/24/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507491
Principal investigator 1 Incyte Corporation $320.00 11/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507372
Principal investigator 1 Incyte Corporation $956.70 11/16/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240507238
Principal investigator 1 ABBVIE INC. $1,698.00 11/13/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202524185
Principal investigator 1 Incyte Corporation $450.00 11/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507423
Principal investigator 1 Incyte Corporation $1,320.00 11/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507448
Principal investigator 1 ABBVIE INC. $7,647.60 11/11/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202523763
Principal investigator 1 Incyte Corporation $1,899.00 11/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507401
Principal investigator 1 Incyte Corporation $1,899.00 11/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507405
Principal investigator 1 Incyte Corporation $677.00 11/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507500
Principal investigator 1 Incyte Corporation $1,321.00 11/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507504
Principal investigator 1 ABBVIE INC. $349.38 11/05/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202522395
Principal investigator 1 ABBVIE INC. $15,475.20 11/05/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522397
Principal investigator 1 ABBVIE INC. $9,390.80 11/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202520659
Principal investigator 1 Incyte Corporation $137.40 11/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507277
Principal investigator 1 Incyte Corporation $369.00 11/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507281
Principal investigator 1 Incyte Corporation $49.36 11/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507333
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507428
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507432
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507436
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507440
Principal investigator 1 Incyte Corporation $4.24 11/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507496
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,747.20 10/22/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287329
Principal investigator 1 Incyte Corporation $629.70 10/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507376
Principal investigator 1 Incyte Corporation $1,244.00 10/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507381
Principal investigator 1 Incyte Corporation $1,244.00 10/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507384
Principal investigator 1 Incyte Corporation $348.00 10/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507476
Principal investigator 1 Incyte Corporation $2,063.00 10/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507479
Principal investigator 1 ABBVIE INC. $984.00 10/16/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202517253
Principal investigator 1 Eli Lilly and Company $5,894.00 10/14/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187877043
Principal investigator 1 ABBVIE INC. $1,820.30 10/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202515113
Principal investigator 1 ABBVIE INC. $759.30 10/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515115
Principal investigator 1 ABBVIE INC. $9,178.50 10/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202515117
Principal investigator 1 ABBVIE INC. $2,168.00 10/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202515285
Principal investigator 1 ABBVIE INC. $1,293.80 10/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202515287
Principal investigator 1 ABBVIE INC. $1,325.60 10/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202515289
Principal investigator 1 Incyte Corporation $660.50 10/08/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507251
Principal investigator 1 Incyte Corporation $1,321.00 10/08/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507255
Principal investigator 1 Incyte Corporation $1,321.00 10/08/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507260
Principal investigator 1 Incyte Corporation $1,321.00 10/08/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507264
Principal investigator 1 Incyte Corporation $1,321.00 10/08/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507269
Principal investigator 1 Incyte Corporation $1,709.10 10/08/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507304
Principal investigator 1 Incyte Corporation $2,063.00 10/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507286
Principal investigator 1 Incyte Corporation $2,063.00 10/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507290
Principal investigator 1 Incyte Corporation $2,063.00 10/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507293
Principal investigator 1 Incyte Corporation $1,348.00 10/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507410
Principal investigator 1 Incyte Corporation $241.50 10/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507464
Principal investigator 1 Incyte Corporation $1,244.00 10/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507468
Principal investigator 1 Incyte Corporation $48.54 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505825
Principal investigator 1 Incyte Corporation $14.84 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505829
Principal investigator 1 Incyte Corporation $64.72 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505833
Principal investigator 1 Incyte Corporation $49.32 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505839
Principal investigator 1 Incyte Corporation $49.32 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505842
Principal investigator 1 Incyte Corporation $49.32 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505846
Principal investigator 1 Incyte Corporation $49.32 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505850
Principal investigator 1 Incyte Corporation $12.72 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505853
Principal investigator 1 Incyte Corporation $54.76 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505859
Principal investigator 1 Incyte Corporation $54.76 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505862
Principal investigator 1 Incyte Corporation $68.70 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505866
Principal investigator 1 Incyte Corporation $57.25 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505869
Principal investigator 1 Incyte Corporation $59.13 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505873
Principal investigator 1 Incyte Corporation $59.13 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505877
Principal investigator 1 Incyte Corporation $41.10 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505880
Principal investigator 1 Incyte Corporation $41.10 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505885
Principal investigator 1 Incyte Corporation $41.10 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505888
Principal investigator 1 Incyte Corporation $41.10 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505893
Principal investigator 1 Incyte Corporation $135.40 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505897
Principal investigator 1 Incyte Corporation $135.40 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505900
Principal investigator 1 Incyte Corporation $49.36 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505904
Principal investigator 1 Incyte Corporation $49.36 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505907
Principal investigator 1 Incyte Corporation $62.27 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505912
Principal investigator 1 Incyte Corporation $62.27 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505916
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,500.00 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1190302249
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,474.90 10/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286131
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,615.63 09/26/2025 Non-covered Recipient Entity
Bellaire Dermatology Associates
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430904
Principal investigator 1 Incyte Corporation $1,000.00 09/23/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240506921
Principal investigator 1 Incyte Corporation $956.70 09/23/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240506930
Principal investigator 1 Incyte Corporation $3,000.00 09/23/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240506933
Principal investigator 1 ABBVIE INC. $150.00 09/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202511638
Principal investigator 1 Incyte Corporation $956.70 09/18/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240506917
Principal investigator 1 Novartis Pharmaceuticals Corporation $66,185.92 09/11/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190302255
Principal investigator 1 Incyte Corporation $660.50 09/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507109
Principal investigator 1 Incyte Corporation $1,321.00 09/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507113
Principal investigator 1 Incyte Corporation $1,321.00 09/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507117
Principal investigator 1 Incyte Corporation $1,321.00 09/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507123
Principal investigator 1 Incyte Corporation $1,321.00 09/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507127
Principal investigator 1 ABBVIE INC. $6,021.90 09/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202508870
Principal investigator 1 ABBVIE INC. $1,244.40 09/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509662
Principal investigator 1 ABBVIE INC. $5,732.40 09/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202509664
Principal investigator 1 Incyte Corporation $2,870.10 09/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240506926
Principal investigator 1 ABBVIE INC. $4,784.90 09/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202508266
Principal investigator 1 ABBVIE INC. $9,353.60 09/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202508270
Principal investigator 1 ABBVIE INC. $11,830.80 09/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202508272
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,977.00 09/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284909
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506994
Principal investigator 1 Incyte Corporation $16.44 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506998
Principal investigator 1 Incyte Corporation $16.44 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507001
Principal investigator 1 Incyte Corporation $16.44 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507006
Principal investigator 1 Incyte Corporation $16.44 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507010
Principal investigator 1 Incyte Corporation $10.60 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507014
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507019
Principal investigator 1 Incyte Corporation $4.24 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507022
Principal investigator 1 Incyte Corporation $24.66 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507027
Principal investigator 1 Incyte Corporation $14.58 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507031
Principal investigator 1 Incyte Corporation $9.72 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507037
Principal investigator 1 Incyte Corporation $24.66 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507041
Principal investigator 1 Incyte Corporation $98.72 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507045
Principal investigator 1 Incyte Corporation $74.04 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507049
Principal investigator 1 Incyte Corporation $16.18 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507052
Principal investigator 1 Incyte Corporation $0.93 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507056
Principal investigator 1 Incyte Corporation $0.31 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507060
Principal investigator 1 Incyte Corporation $24.68 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507065
Principal investigator 1 Incyte Corporation $48.54 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507084
Principal investigator 1 Incyte Corporation $4.86 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507131
Principal investigator 1 Incyte Corporation $45.80 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507135
Principal investigator 1 Incyte Corporation $34.35 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507138
Principal investigator 1 Incyte Corporation $16.44 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507142
Principal investigator 1 Incyte Corporation $16.44 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507148
Principal investigator 1 Incyte Corporation $16.44 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507152
Principal investigator 1 Incyte Corporation $16.44 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507157
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507179
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507184
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507188
Principal investigator 1 Incyte Corporation $16.18 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507196
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507212
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507216
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507221
Principal investigator 1 Incyte Corporation $24.66 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507226
Principal investigator 1 Incyte Corporation $24.66 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507231
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,000.00 09/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190302253
Principal investigator 1 ABBVIE INC. $1,440.00 08/21/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505329
Principal investigator 1 ABBVIE INC. $429.00 08/21/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202505331
Principal investigator 1 ABBVIE INC. $3,372.00 08/21/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202505333
Principal investigator 1 ABBVIE INC. $3,321.00 08/21/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202505457
Principal investigator 1 ABBVIE INC. $3,302.00 08/21/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202505459
Principal investigator 1 ABBVIE INC. $3,302.00 08/21/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202505471
Principal investigator 1 ABBVIE INC. $650.50 08/21/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202505473
Principal investigator 1 Incyte Corporation $348.00 08/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506937
Principal investigator 1 Incyte Corporation $858.80 08/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506941
Principal investigator 1 Incyte Corporation $1,244.00 08/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506945
Principal investigator 1 Incyte Corporation $2,063.00 08/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506953
Principal investigator 1 Incyte Corporation $1,244.00 08/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507097
Principal investigator 1 Incyte Corporation $1,244.00 08/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507101
Principal investigator 1 Incyte Corporation $1,348.00 08/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507105
Principal investigator 1 Incyte Corporation $1,244.00 08/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507200
Principal investigator 1 Incyte Corporation $1,244.00 08/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507205
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,065.00 08/20/2025 Non-covered Recipient Entity
Bellaire Dermatology Associates
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430902
Principal investigator 1 ABBVIE INC. $778.70 08/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202503059
Principal investigator 1 ABBVIE INC. $5,287.20 08/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202503071
Principal investigator 1 ABBVIE INC. $27,056.40 08/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503077
Principal investigator 1 ABBVIE INC. $1,890.50 08/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202503191
Principal investigator 1 ABBVIE INC. $1,321.00 08/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202503193
Principal investigator 1 ABBVIE INC. $4,055.60 08/05/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501158
Principal investigator 1 ABBVIE INC. $1,299.00 08/05/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501160
Principal investigator 1 ABBVIE INC. $13,337.60 08/05/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202501860
Principal investigator 1 ABBVIE INC. $15,201.30 08/05/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202501862
Principal investigator 1 Incyte Corporation $924.70 08/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506963
Principal investigator 1 Incyte Corporation $1,321.00 08/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506967
Principal investigator 1 Incyte Corporation $1,321.00 08/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506983
Principal investigator 1 Incyte Corporation $22.90 08/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507068
Principal investigator 1 Incyte Corporation $49.36 08/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507073
Principal investigator 1 Incyte Corporation $0.62 08/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507076
Principal investigator 1 Incyte Corporation $32.36 08/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507080
Principal investigator 1 Incyte Corporation $22.90 08/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507089
Principal investigator 1 Incyte Corporation $49.36 08/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507093
Principal investigator 1 Incyte Corporation $1,387.10 08/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506975
Principal investigator 1 Incyte Corporation $1,321.00 08/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506990
Principal investigator 1 Incyte Corporation $1,899.00 08/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507192
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,865.90 08/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283405
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,401.40 08/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283407
Principal investigator 1 Eli Lilly and Company $2,766.00 07/22/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187876005
Principal investigator 1 Eli Lilly and Company $1,500.00 07/22/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187877787
Principal investigator 1 Incyte Corporation $1,403.60 07/18/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506971
Principal investigator 1 Incyte Corporation $1,348.00 07/18/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506979
Principal investigator 1 Incyte Corporation $1,939.00 07/18/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506987
Principal investigator 1 Incyte Corporation $1,244.00 07/18/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507160
Principal investigator 1 Incyte Corporation $260.00 07/11/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507209
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 07/11/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223282590
Principal investigator 1 Incyte Corporation $660.50 07/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506949
Principal investigator 1 Incyte Corporation $164.00 07/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506956
Principal investigator 1 Incyte Corporation $1,321.00 07/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506959
Principal investigator 1 Incyte Corporation $1,321.00 07/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507163
Principal investigator 1 Incyte Corporation $1,321.00 07/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507167
Principal investigator 1 Incyte Corporation $1,321.00 07/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507172
Principal investigator 1 Incyte Corporation $1,188.90 07/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240507176
Principal investigator 1 ABBVIE INC. $1,293.80 07/08/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497194
Principal investigator 1 ABBVIE INC. $11,652.00 07/08/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202497332
Principal investigator 1 ABBVIE INC. $6,709.60 07/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202495789
Principal investigator 1 ABBVIE INC. $8,129.10 07/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202495797
Principal investigator 1 ABBVIE INC. $5,577.60 07/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202495817
Principal investigator 1 ABBVIE INC. $1,746.20 07/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202495825
Principal investigator 1 ABBVIE INC. $6,087.00 07/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496277
Principal investigator 1 ABBVIE INC. $1,556.00 07/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202493821
Principal investigator 1 Novartis Pharmaceuticals Corporation $264.00 07/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190304603
Principal investigator 1 ABBVIE INC. $17,042.40 06/26/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202493249
Principal investigator 1 Incyte Corporation $824.90 06/25/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506564
Principal investigator 1 Incyte Corporation $348.00 06/25/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506583
Principal investigator 1 Incyte Corporation $1,244.00 06/25/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506587
Principal investigator 1 Incyte Corporation $1,939.00 06/25/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506591
Principal investigator 1 Incyte Corporation $1,939.00 06/25/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506595
Principal investigator 1 Incyte Corporation $1,244.00 06/25/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506602
Principal investigator 1 Incyte Corporation $1,244.00 06/25/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506875
Principal investigator 1 Incyte Corporation $1,244.00 06/25/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506880
Principal investigator 1 Incyte Corporation $750.00 06/23/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506611
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,520.35 06/20/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223281720
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,896.88 06/18/2025 Non-covered Recipient Entity
Bellaire Dermatology Associates
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430900
Principal investigator 1 Incyte Corporation $520.00 06/13/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506599
Principal investigator 1 Incyte Corporation $375.00 06/13/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506607
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,649.70 06/13/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281268
Principal investigator 1 Incyte Corporation $1,444.90 06/11/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506615
Principal investigator 1 Incyte Corporation $1,321.00 06/11/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506619
Principal investigator 1 Incyte Corporation $1,321.00 06/11/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506913
Principal investigator 1 Incyte Corporation $1,321.00 06/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506627
Principal investigator 1 Incyte Corporation $792.60 06/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506883
Principal investigator 1 Incyte Corporation $1,321.00 06/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506888
Principal investigator 1 Incyte Corporation $1,321.00 06/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506892
Principal investigator 1 Janssen Research & Development, LLC $156.00 06/04/2025 Non-covered Recipient Entity
Bellaire Derm
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175277807
Principal investigator 1 Janssen Research & Development, LLC $201.00 06/04/2025 Non-covered Recipient Entity
Bellaire Derm
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175277901
Principal investigator 1 ABBVIE INC. $1,700.70 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202488413
Principal investigator 1 ABBVIE INC. $6,230.50 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202488465
Principal investigator 1 ABBVIE INC. $10,270.80 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202488559
Principal investigator 1 ABBVIE INC. $6,791.20 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202488677
Principal investigator 1 ABBVIE INC. $5,265.00 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202488781
Principal investigator 1 Incyte Corporation $74.04 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506708
Principal investigator 1 Incyte Corporation $80.15 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506712
Principal investigator 1 Incyte Corporation $123.40 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506715
Principal investigator 1 Incyte Corporation $11.45 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506719
Principal investigator 1 Incyte Corporation $41.10 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506723
Principal investigator 1 Incyte Corporation $41.10 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506727
Principal investigator 1 Incyte Corporation $32.36 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506731
Principal investigator 1 Incyte Corporation $14.58 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506735
Principal investigator 1 Incyte Corporation $10.60 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506739
Principal investigator 1 Incyte Corporation $0.93 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506743
Principal investigator 1 Incyte Corporation $41.10 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506749
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506756
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506760
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506764
Principal investigator 1 Incyte Corporation $24.66 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506768
Principal investigator 1 Incyte Corporation $60.77 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506814
Principal investigator 1 Incyte Corporation $41.10 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506903
Principal investigator 1 Incyte Corporation $38.11 06/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506908
Principal investigator 1 Janssen Research & Development, LLC $180.00 06/02/2025 Non-covered Recipient Entity
Bellaire Derm
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175277886
Principal investigator 1 Incyte Corporation $2,063.00 05/21/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506555
Principal investigator 1 Incyte Corporation $1,244.00 05/21/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506559
Principal investigator 1 Incyte Corporation $788.90 05/21/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,441.40 05/14/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223279790
Principal investigator 1 ABBVIE INC. $6,084.00 05/08/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202484383
Principal investigator 1 ABBVIE INC. $4,428.70 05/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202482977
Principal investigator 1 ABBVIE INC. $9,286.20 05/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482979
Principal investigator 1 ABBVIE INC. $6,276.30 05/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202482981
Principal investigator 1 ABBVIE INC. $22,571.10 05/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202482983
Principal investigator 1 Incyte Corporation $727.50 05/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506818
Principal investigator 1 Incyte Corporation $1,455.00 05/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506822
Principal investigator 1 Incyte Corporation $1,455.00 05/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506827
Principal investigator 1 Incyte Corporation $1,455.00 05/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506831
Principal investigator 1 Incyte Corporation $1,455.00 05/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,558.50 05/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223279152
Principal investigator 1 ABBVIE INC. $11,131.60 05/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202481587
Principal investigator 1 ABBVIE INC. $2,387.40 05/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481589
Principal investigator 1 Incyte Corporation $1,939.00 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506521
Principal investigator 1 Incyte Corporation $1,244.00 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506524
Principal investigator 1 Incyte Corporation $1,244.00 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506530
Principal investigator 1 Incyte Corporation $792.60 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506569
Principal investigator 1 Incyte Corporation $1,244.00 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506573
Principal investigator 1 Incyte Corporation $1,244.00 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506578
Principal investigator 1 Incyte Corporation $65.76 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506635
Principal investigator 1 Incyte Corporation $311.35 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506639
Principal investigator 1 Incyte Corporation $677.00 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506641
Principal investigator 1 Incyte Corporation $19.08 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506645
Principal investigator 1 Incyte Corporation $194.65 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506650
Principal investigator 1 Incyte Corporation $64.72 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506659
Principal investigator 1 Incyte Corporation $148.08 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506663
Principal investigator 1 Incyte Corporation $295.65 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506772
Principal investigator 1 Incyte Corporation $65.76 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506803
Principal investigator 1 Incyte Corporation $65.76 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506807
Principal investigator 1 Incyte Corporation $65.76 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506810
Principal investigator 1 Incyte Corporation $859.70 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506839
Principal investigator 1 Incyte Corporation $1,939.00 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506843
Principal investigator 1 Incyte Corporation $1,321.00 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506852
Principal investigator 1 Incyte Corporation $1,321.00 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506857
Principal investigator 1 Incyte Corporation $1,321.00 05/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506861
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 04/28/2025 Non-covered Recipient Entity
Bellaire Derm
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175277623
Principal investigator 1 ABBVIE INC. $672.00 04/16/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202476917
Principal investigator 1 ABBVIE INC. $3,843.90 04/16/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202476926
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,994.60 04/16/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223278116
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,555.00 04/11/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277958
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,257.10 04/11/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278056
Principal investigator 1 ABBVIE INC. $873.60 04/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202475696
Principal investigator 1 ABBVIE INC. $226.20 04/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202475700
Principal investigator 1 ABBVIE INC. $741.00 04/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202475727
Principal investigator 1 Incyte Corporation $1,188.90 04/09/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506534
Principal investigator 1 Incyte Corporation $1,455.00 04/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506538
Principal investigator 1 Incyte Corporation $979.30 04/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506543
Principal investigator 1 Incyte Corporation $1,406.00 04/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506900
Principal investigator 1 ABBVIE INC. $3,596.70 04/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470467
Principal investigator 1 ABBVIE INC. $9,381.60 04/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202470650
Principal investigator 1 ABBVIE INC. $1,421.20 04/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202470655
Principal investigator 1 ABBVIE INC. $349.38 04/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202470816
Principal investigator 1 ABBVIE INC. $1,341.90 04/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202470821
Principal investigator 1 ABBVIE INC. $12,240.00 04/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470827
Principal investigator 1 ABBVIE INC. $8,317.20 04/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202471208
Principal investigator 1 Incyte Corporation $850.00 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506541
Principal investigator 1 Incyte Corporation $1,348.00 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506547
Principal investigator 1 Incyte Corporation $1,348.00 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506551
Principal investigator 1 Incyte Corporation $22.66 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506623
Principal investigator 1 Incyte Corporation $8.48 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506631
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506655
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506667
Principal investigator 1 Incyte Corporation $37.66 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506672
Principal investigator 1 Incyte Corporation $54.76 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506677
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506681
Principal investigator 1 Incyte Corporation $153.70 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506684
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506687
Principal investigator 1 Incyte Corporation $121.90 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506692
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506696
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506699
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506703
Principal investigator 1 Incyte Corporation $190.80 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506776
Principal investigator 1 Incyte Corporation $49.44 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506780
Principal investigator 1 Incyte Corporation $32.88 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506785
Principal investigator 1 Incyte Corporation $32.88 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506789
Principal investigator 1 Incyte Corporation $32.88 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506794
Principal investigator 1 Incyte Corporation $32.88 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506797
Principal investigator 1 Incyte Corporation $37.66 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506848
Principal investigator 1 Incyte Corporation $249.10 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506869
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506872
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506896
Principal investigator 1 SANOFI US SERVICES INC. $10,800.00 04/02/2025 Non-covered Recipient Entity
Bellaire Dermatology Associates Pa
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226086551
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 03/24/2025 Non-covered Recipient Entity
Bellaire Derm Assoc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175277854
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,768.75 03/24/2025 Non-covered Recipient Entity
Bellaire Dermatology Associates
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430898
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,961.75 03/14/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223276727
Principal investigator 1 Incyte Corporation $924.70 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506074
Principal investigator 1 Incyte Corporation $1,321.00 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506078
Principal investigator 1 Incyte Corporation $1,321.00 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506083
Principal investigator 1 Incyte Corporation $304.00 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506087
Principal investigator 1 Incyte Corporation $1,444.00 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506091
Principal investigator 1 Incyte Corporation $1,406.00 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506415
Principal investigator 1 Incyte Corporation $1,406.00 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506418
Principal investigator 1 Incyte Corporation $1,406.00 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506423
Principal investigator 1 Incyte Corporation $1,406.00 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506427
Principal investigator 1 Incyte Corporation $1,444.00 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506511
Principal investigator 1 Incyte Corporation $1,444.00 03/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506516
Principal investigator 1 ABBVIE INC. $2,538.20 03/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202459554
Principal investigator 1 ABBVIE INC. $10,085.70 03/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202459760
Principal investigator 1 ABBVIE INC. $10,192.80 03/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202459764
Principal investigator 1 ABBVIE INC. $3,183.00 03/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202459767
Principal investigator 1 ABBVIE INC. $102.00 03/07/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202459821
Principal investigator 1 ABBVIE INC. $1,120.90 03/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202456687
Principal investigator 1 ABBVIE INC. $7,036.00 03/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202456764
Principal investigator 1 Eli Lilly and Company $68,227.00 03/04/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187874845
Principal investigator 1 Incyte Corporation $1,354.00 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505966
Principal investigator 1 Incyte Corporation $1,348.00 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506096
Principal investigator 1 Incyte Corporation $1,348.00 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506100
Principal investigator 1 Incyte Corporation $1,939.00 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506108
Principal investigator 1 Incyte Corporation $908.40 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506112
Principal investigator 1 Incyte Corporation $547.60 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506260
Principal investigator 1 Incyte Corporation $591.30 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506264
Principal investigator 1 Incyte Corporation $273.80 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506268
Principal investigator 1 Incyte Corporation $148.08 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506271
Principal investigator 1 Incyte Corporation $172.76 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506276
Principal investigator 1 Incyte Corporation $97.08 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506280
Principal investigator 1 Incyte Corporation $97.08 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506283
Principal investigator 1 Incyte Corporation $591.30 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506287
Principal investigator 1 Incyte Corporation $1,354.00 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506291
Principal investigator 1 Incyte Corporation $240.45 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506295
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506298
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506300
Principal investigator 1 Incyte Corporation $46.17 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506306
Principal investigator 1 Incyte Corporation $29.16 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506310
Principal investigator 1 Incyte Corporation $57.54 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506314
Principal investigator 1 Incyte Corporation $12.15 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506318
Principal investigator 1 Incyte Corporation $3.10 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506321
Principal investigator 1 Incyte Corporation $622.70 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506326
Principal investigator 1 Incyte Corporation $24.30 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506331
Principal investigator 1 Incyte Corporation $1,244.00 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506335
Principal investigator 1 Incyte Corporation $1,244.00 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506339
Principal investigator 1 Incyte Corporation $1,244.00 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506342
Principal investigator 1 Incyte Corporation $1.86 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506347
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506366
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506370
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506376
Principal investigator 1 Incyte Corporation $57.54 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506487
Principal investigator 1 Incyte Corporation $57.54 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506490
Principal investigator 1 Incyte Corporation $57.54 03/03/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506494
Principal investigator 1 Janssen Research & Development, LLC $3,466.00 02/27/2025 Non-covered Recipient Entity
Bellaire Derm Assoc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175277640
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 02/27/2025 Non-covered Recipient Entity
Bellaire Derm Assoc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175277656
Principal investigator 1 Janssen Research & Development, LLC $3,466.00 02/27/2025 Non-covered Recipient Entity
Bellaire Derm Assoc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175277783
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,756.50 02/26/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275667
Principal investigator 1 ABBVIE INC. $1,000.00 02/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202452525
Principal investigator 1 Incyte Corporation $13.30 02/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505997
Principal investigator 1 Incyte Corporation $1,444.00 02/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506001
Principal investigator 1 Incyte Corporation $618.10 02/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506007
Principal investigator 1 Incyte Corporation $2,078.00 02/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506010
Principal investigator 1 Incyte Corporation $1,321.00 02/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506350
Principal investigator 1 Incyte Corporation $2,078.00 02/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506449
Principal investigator 1 Incyte Corporation $2,078.00 02/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506457
Principal investigator 1 Incyte Corporation $2,078.00 02/19/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506462
Principal investigator 1 ABBVIE INC. $136.00 02/18/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202452337
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,890.05 02/12/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275197
Principal investigator 1 Incyte Corporation $1,175.50 02/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506015
Principal investigator 1 Incyte Corporation $633.70 02/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506019
Principal investigator 1 Incyte Corporation $1,321.00 02/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506024
Principal investigator 1 Incyte Corporation $1,455.00 02/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506028
Principal investigator 1 Incyte Corporation $1,455.00 02/10/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506032
Principal investigator 1 ABBVIE INC. $20,596.20 02/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202446959
Principal investigator 1 ABBVIE INC. $1,236.25 02/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202446964
Principal investigator 1 ABBVIE INC. $51.00 02/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202446967
Principal investigator 1 ABBVIE INC. $9,235.70 02/06/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202447053
Principal investigator 1 ABBVIE INC. $6,055.30 02/05/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202444003
Principal investigator 1 ABBVIE INC. $15,058.40 02/05/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202444019
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,813.40 02/01/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190304605
Principal investigator 1 Amgen Inc. $22,153.81 01/27/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639591
Principal investigator 1 Eli Lilly and Company $2,885.29 01/27/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187876397
Principal investigator 1 Incyte Corporation $207.20 01/27/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506036
Principal investigator 1 Incyte Corporation $1,244.00 01/27/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506041
Principal investigator 1 Incyte Corporation $1,244.00 01/27/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506061
Principal investigator 1 Incyte Corporation $1,244.00 01/27/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506065
Principal investigator 1 Incyte Corporation $1,348.00 01/27/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506431
Principal investigator 1 Incyte Corporation $1,348.00 01/27/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506436
Principal investigator 1 Incyte Corporation $1,348.00 01/27/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506440
Principal investigator 1 Incyte Corporation $1,348.00 01/27/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506445
Principal investigator 1 Janssen Research & Development, LLC $1,228.00 01/27/2025 Non-covered Recipient Entity
Bellaire Derm Assoc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175277719
Principal investigator 1 Janssen Research & Development, LLC $1,228.00 01/27/2025 Non-covered Recipient Entity
Bellaire Derm Assoc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175277932
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,305.24 01/17/2025 Non-covered Recipient Entity
Bellaire Dermatology
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235998692
Principal investigator 1 Incyte Corporation $1,406.00 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506044
Principal investigator 1 Incyte Corporation $1,406.00 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506049
Principal investigator 1 Incyte Corporation $1,406.00 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506053
Principal investigator 1 Incyte Corporation $1,406.00 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506057
Principal investigator 1 Incyte Corporation $2,078.00 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506070
Principal investigator 1 Incyte Corporation $1,321.00 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506395
Principal investigator 1 Incyte Corporation $1,321.00 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506400
Principal investigator 1 Incyte Corporation $1,321.00 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506404
Principal investigator 1 Incyte Corporation $1,321.00 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506407
Principal investigator 1 Incyte Corporation $1,321.00 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506411
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,035.30 01/17/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATE
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223274229
Principal investigator 1 Incyte Corporation $351.60 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505969
Principal investigator 1 Incyte Corporation $348.00 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505974
Principal investigator 1 Incyte Corporation $1,455.00 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505982
Principal investigator 1 Incyte Corporation $1,348.00 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240505993
Principal investigator 1 Incyte Corporation $1,244.00 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506004
Principal investigator 1 Incyte Corporation $1,348.00 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506355
Principal investigator 1 Incyte Corporation $1,348.00 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506358
Principal investigator 1 Incyte Corporation $1,348.00 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506362
Principal investigator 1 Incyte Corporation $348.00 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506501
Principal investigator 1 Incyte Corporation $348.00 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506506
Principal investigator 1 Novartis Pharmaceuticals Corporation $19.88 01/15/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1190304601
Principal investigator 1 ABBVIE INC. $2,842.40 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202433537
Principal investigator 1 ABBVIE INC. $3,107.30 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202433582
Principal investigator 1 ABBVIE INC. $537.75 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202433585
Principal investigator 1 Incyte Corporation $265.00 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506105
Principal investigator 1 Incyte Corporation $270.30 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506118
Principal investigator 1 Incyte Corporation $291.50 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506122
Principal investigator 1 Incyte Corporation $38.88 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506128
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506132
Principal investigator 1 Incyte Corporation $254.40 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506135
Principal investigator 1 Incyte Corporation $180.20 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506140
Principal investigator 1 Incyte Corporation $174.90 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506144
Principal investigator 1 Incyte Corporation $53.80 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506147
Principal investigator 1 Incyte Corporation $259.70 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506151
Principal investigator 1 Incyte Corporation $227.90 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506157
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506162
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506168
Principal investigator 1 Incyte Corporation $172.76 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506172
Principal investigator 1 Incyte Corporation $114.50 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506176
Principal investigator 1 Incyte Corporation $113.26 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506180
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506184
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506187
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506191
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506193
Principal investigator 1 Incyte Corporation $114.50 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506199
Principal investigator 1 Incyte Corporation $5.38 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506203
Principal investigator 1 Incyte Corporation $57.54 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506206
Principal investigator 1 Incyte Corporation $10.60 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506210
Principal investigator 1 Incyte Corporation $10.60 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506215
Principal investigator 1 Incyte Corporation $41.31 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506219
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506223
Principal investigator 1 Incyte Corporation $5.27 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506227
Principal investigator 1 Incyte Corporation $2.17 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506231
Principal investigator 1 Incyte Corporation $148.08 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506235
Principal investigator 1 Incyte Corporation $49.32 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506238
Principal investigator 1 Incyte Corporation $49.32 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506242
Principal investigator 1 Incyte Corporation $49.32 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506247
Principal investigator 1 Incyte Corporation $49.32 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506251
Principal investigator 1 Incyte Corporation $113.26 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506255
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506380
Principal investigator 1 Incyte Corporation $111.30 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506384
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506387
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506392
Principal investigator 1 Incyte Corporation $5.38 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506466
Principal investigator 1 Incyte Corporation $53.80 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506470
Principal investigator 1 Incyte Corporation $57.54 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506473
Principal investigator 1 Incyte Corporation $57.54 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506478
Principal investigator 1 Incyte Corporation $57.54 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506483
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
BELLAIRE DERMATOLOGY ASSOCIATES BDA
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240506497